Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M2R as a Marker of Risk of iALTE in Infants
NCT03278977Terminated
- Sponsor
- Strasbourg University Hospital
- Start
- Sep 2018
- Primary completion
- May 2022
- Countries
- 1
01
Overview
Trial (2 arms), sponsored by Strasbourg University Hospital. Primary endpoint: Muscarinic M2 receptor mRNA expression in blood. Started Sep 2018; status: terminated.
Beyond the preview
Go deeper on NCT03278977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03278977.